These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 3159336)

  • 1. Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs.
    Gordin FM; Hackbarth CJ; Scott KG; Sande MA
    Antimicrob Agents Chemother; 1985 Apr; 27(4):452-4. PubMed ID: 3159336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.
    Rusnak MG; Drake TA; Hackbarth CJ; Sande MA
    J Infect Dis; 1984 Jun; 149(6):980-5. PubMed ID: 6429255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Hoogkamp-Korstanje JA
    Eur J Clin Microbiol; 1984 Aug; 3(4):333-8. PubMed ID: 6237901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Kemmerich B; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1986 Mar; 29(3):395-9. PubMed ID: 2940970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
    Schiff JB; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1984 Jul; 26(1):1-4. PubMed ID: 6433786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies.
    D'Antonio D; Piccolomini R; Iacone A; Fioritoni G; Parruti G; Betti S; Quaglietta AM; Accorsi P; Dell'Isola M; Favalli C
    J Antimicrob Chemother; 1994 Apr; 33(4):837-44. PubMed ID: 8056702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ciprofloxacin against clinical isolates of Chlamydia trachomatis.
    Meier-Ewert H; Weil G; Millott G
    Eur J Clin Microbiol; 1984 Aug; 3(4):372. PubMed ID: 6593220
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative in vitro study of the activity of 5 quinolones against Acinetobacter calcoaceticus].
    Joly-Guillou ML; Bergogne-Berezin E
    Pathol Biol (Paris); 1985 May; 33(5):416-20. PubMed ID: 3162142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin.
    Bendig JW; Kyle PW; Giangrande PL; Samson DM; Azadian BS
    J R Soc Med; 1987 May; 80(5):316-7. PubMed ID: 3112380
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice.
    Fu KP; Hetzel N; Gregory FJ; Hung PP
    J Antimicrob Chemother; 1987 Oct; 20(4):541-6. PubMed ID: 3680089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vitro and in vivo activity of ciprofloxacin.
    Zeiler HJ; Grohe K
    Eur J Clin Microbiol; 1984 Aug; 3(4):339-43. PubMed ID: 6237902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro antibacterial activity of three new quinolone derivatives: rosoxacin, norfloxacin, pefloxacin.
    Husson MO; Izard D; Leclerc H
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Dec; 258(2-3):283-6. PubMed ID: 6241772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.
    Follath F; Bindschedler M; Wenk M; Frei R; Stalder H; Reber H
    Eur J Clin Microbiol; 1986 Apr; 5(2):236-40. PubMed ID: 2941289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of pefloxacin compared with six other quinolones.
    Ligtvoet EE; Wickerhoff-Minoggio T
    J Antimicrob Chemother; 1985 Oct; 16(4):485-90. PubMed ID: 3864776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.